MDMA’s Latest Trial Results Offer Hope for Patients with PTSD
A clinical trial showed that MDMA, the so-called psychedelic drug also known as "ecstasy" or "molly," can be a powerful new tool in treating people with moderate-to-severe PTSD.
University of California San Francisco
Give to UCSFA clinical trial showed that MDMA, the so-called psychedelic drug also known as "ecstasy" or "molly," can be a powerful new tool in treating people with moderate-to-severe PTSD.
A new intervention may help “night owl” kids adjust to their natural sleep-cycle rhythms, fulfill their school responsibilities and avoid depression.
An Oregon prison is testing a Norwegian-inspired approach to prison reform that’s designed to bring greater humanity to corrections and improve conditions for staff and prison residents. This includes reducing the use of solitary confinement.
A brain implant and digital avatar allow a paralyzed stroke survivor to speak with for first time in 18 years with the help of artificial intelligence.
UCSF Langley Porter Psychiatric Hospital will welcome patients to a larger and modernized space on August 19 in UCSF Mount Zion Medical Center.
A newly identified platelet factor 4 (PF4) was found to help rejuvenate the old brain and boost the young brain, potentially opening the door to new therapies that aim to restore brain function
A new digital headset designed to measure alterations in brain function could change decisions about how quickly an athlete is ready to return to play after a concussion.
Adverse experiences early in childhood and early life have been linked to lifelong health consequences.
UCSF Medical Center has been ranked among the country’s best hospitals in adult care in U.S. News & World Report’s prestigious Best Hospitals survey.
An experimental blood test that reflects injury to nerve cells from multiple sclerosis (MS) was found to work for children with MS and other neurological conditions, even when they are symptom-free.